Search Results

THINK Surgical, Inc. announced that it will enter into a new Collaboration Agreement with b-ONE Ortho Corporation.

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Trivicta™ Hip System.

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced the launch of BKS® Uni, the latest addition to its portfolio of Balanced Knee® implant systems.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently announced the launch of the Podiatry Board Review Challenge, a new professional educational resource.

Ortho Regenerative Technologies Inc. announced today that it has received, through its partnership with Polytechnique Montreal, a $500,000 non-dilutive grant from Axelys, to advance the development of its second technology platform indication, ORTHO-M, for meniscus repair.

Ortho Regenerative Technologies Inc. announced today that the United States Patent and Trademark Office (the “USPTO”) has issued a patent related to the Company’s ORTHO-R soft tissue repair platform.

Ortho Regenerative Technologies Inc. announced that it has changed its corporate name to ChitogenX Inc. to better reflect the Company’s expanded clinical and commercial opportunities, mission, values, and core competencies.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action date of October 20, 2023.